Semaglutide Reduces Alzheimer’s Risk in Diabetics
A recent study shows that semaglutide, used in diabetes medications like Ozempic and Wegovy, significantly reduces the risk of Alzheimer’s disease (AD) in patients with Type 2 diabetes. Patients on semaglutide experienced a 40%-70% lower risk of developing AD compared to those on other diabetes treatments. Semaglutide works by reducing harmful proteins and inflammation in the brain. These findings are especially significant for India, which has a high prevalence of diabetes. Further research on GLP-1 receptor agonists could lead to new therapeutic strategies for managing both diabetes and dementia.
If you like this post, please share your feedback in the comments section below so that we will upload more posts like this.
